NCT06760364 tests CHT102, an allogeneic (off-the-shelf) UCAR‑T cell therapy delivered by arterial infusion for mesothelin (MSLN)-positive advanced pancreatic cancer. Mechanism: donor-derived T cells are engineered with a chimeric antigen receptor that specifically binds MSLN on tumor cells, CAR engagement activates T‑cell cytotoxic programs (immune synapse formation, perforin/granzyme release, cytokine secretion) leading to lysis of MSLN-expressing cells. Targets: mesothelin on pancreatic tumor cells, effector cells are CAR‑modified T lymphocytes, key pathways modulated include CAR/TCR signaling and downstream immune-mediated cytotoxicity. Phase 1, single-arm, open-label, endpoints include safety, preliminary efficacy, and PK.